Overexpression of VEGF121, but not VEGF165 or FGF-1, improves oxygenation in MCF-7 breast tumours

B. M. Fenton*, S. F. Paoni, W. Liu, S. Y. Cheng, B. Hu, I. Ding

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) is an intensively studied molecule that has significant potential, both in stimulating angiogenesis and as a target for antiangiogenic approaches. We utilised MCF-7 breast cancer cells transfected with either of two of the major VEGF isoforms, VEGF 121 or VEGF165, or fibroblast growth factor-1 (FGF-1) to distinguish the effects of these factors on tumour growth, vascular function, and oxygen delivery. While each transfectant demonstrated substantially increased tumorigenicity and growth rate compared to vector controls, only VEGF121 produced a combination of significantly reduced total and perfused vessel spacing, as well as a corresponding reduction in overall tumour hypoxia. Such pathophysiological effects are of potential importance, since antiangiogenic agents designed to block VEGF isoforms could in turn result in the development of therapeutically unfavourable environments. If antiangiogenic agents are also combined with conventional therapies such as irradiation or chemotherapy, microregional deficiencies in oxygenation could play a key role in ultimate therapeutic success.

Original languageEnglish (US)
Pages (from-to)430-435
Number of pages6
JournalBritish Journal of Cancer
Volume90
Issue number2
DOIs
StatePublished - Jan 26 2004

Fingerprint

Fibroblast Growth Factor 1
Vascular Endothelial Growth Factor A
Breast Neoplasms
Angiogenesis Inhibitors
Protein Isoforms
Growth
Blood Vessels
Oxygen
Drug Therapy
Therapeutics
Neoplasms

Keywords

  • Antiangiogenic
  • Hypoxia
  • Image analysis
  • Perfusion
  • Tumour vasculature

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{44948ed549bf4dec98937fa8e8e946ee,
title = "Overexpression of VEGF121, but not VEGF165 or FGF-1, improves oxygenation in MCF-7 breast tumours",
abstract = "Vascular endothelial growth factor (VEGF) is an intensively studied molecule that has significant potential, both in stimulating angiogenesis and as a target for antiangiogenic approaches. We utilised MCF-7 breast cancer cells transfected with either of two of the major VEGF isoforms, VEGF 121 or VEGF165, or fibroblast growth factor-1 (FGF-1) to distinguish the effects of these factors on tumour growth, vascular function, and oxygen delivery. While each transfectant demonstrated substantially increased tumorigenicity and growth rate compared to vector controls, only VEGF121 produced a combination of significantly reduced total and perfused vessel spacing, as well as a corresponding reduction in overall tumour hypoxia. Such pathophysiological effects are of potential importance, since antiangiogenic agents designed to block VEGF isoforms could in turn result in the development of therapeutically unfavourable environments. If antiangiogenic agents are also combined with conventional therapies such as irradiation or chemotherapy, microregional deficiencies in oxygenation could play a key role in ultimate therapeutic success.",
keywords = "Antiangiogenic, Hypoxia, Image analysis, Perfusion, Tumour vasculature",
author = "Fenton, {B. M.} and Paoni, {S. F.} and W. Liu and Cheng, {S. Y.} and B. Hu and I. Ding",
year = "2004",
month = "1",
day = "26",
doi = "10.1038/sj.bjc.6601539",
language = "English (US)",
volume = "90",
pages = "430--435",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

Overexpression of VEGF121, but not VEGF165 or FGF-1, improves oxygenation in MCF-7 breast tumours. / Fenton, B. M.; Paoni, S. F.; Liu, W.; Cheng, S. Y.; Hu, B.; Ding, I.

In: British Journal of Cancer, Vol. 90, No. 2, 26.01.2004, p. 430-435.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Overexpression of VEGF121, but not VEGF165 or FGF-1, improves oxygenation in MCF-7 breast tumours

AU - Fenton, B. M.

AU - Paoni, S. F.

AU - Liu, W.

AU - Cheng, S. Y.

AU - Hu, B.

AU - Ding, I.

PY - 2004/1/26

Y1 - 2004/1/26

N2 - Vascular endothelial growth factor (VEGF) is an intensively studied molecule that has significant potential, both in stimulating angiogenesis and as a target for antiangiogenic approaches. We utilised MCF-7 breast cancer cells transfected with either of two of the major VEGF isoforms, VEGF 121 or VEGF165, or fibroblast growth factor-1 (FGF-1) to distinguish the effects of these factors on tumour growth, vascular function, and oxygen delivery. While each transfectant demonstrated substantially increased tumorigenicity and growth rate compared to vector controls, only VEGF121 produced a combination of significantly reduced total and perfused vessel spacing, as well as a corresponding reduction in overall tumour hypoxia. Such pathophysiological effects are of potential importance, since antiangiogenic agents designed to block VEGF isoforms could in turn result in the development of therapeutically unfavourable environments. If antiangiogenic agents are also combined with conventional therapies such as irradiation or chemotherapy, microregional deficiencies in oxygenation could play a key role in ultimate therapeutic success.

AB - Vascular endothelial growth factor (VEGF) is an intensively studied molecule that has significant potential, both in stimulating angiogenesis and as a target for antiangiogenic approaches. We utilised MCF-7 breast cancer cells transfected with either of two of the major VEGF isoforms, VEGF 121 or VEGF165, or fibroblast growth factor-1 (FGF-1) to distinguish the effects of these factors on tumour growth, vascular function, and oxygen delivery. While each transfectant demonstrated substantially increased tumorigenicity and growth rate compared to vector controls, only VEGF121 produced a combination of significantly reduced total and perfused vessel spacing, as well as a corresponding reduction in overall tumour hypoxia. Such pathophysiological effects are of potential importance, since antiangiogenic agents designed to block VEGF isoforms could in turn result in the development of therapeutically unfavourable environments. If antiangiogenic agents are also combined with conventional therapies such as irradiation or chemotherapy, microregional deficiencies in oxygenation could play a key role in ultimate therapeutic success.

KW - Antiangiogenic

KW - Hypoxia

KW - Image analysis

KW - Perfusion

KW - Tumour vasculature

UR - http://www.scopus.com/inward/record.url?scp=1342344001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342344001&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601539

DO - 10.1038/sj.bjc.6601539

M3 - Article

C2 - 14735189

AN - SCOPUS:1342344001

VL - 90

SP - 430

EP - 435

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -